Analysis of Nanomedicine Applications for Inflammatory Bowel Disease: Structural and Temporal Dynamics, Research Hotspots, and Emerging Trends

Overview

Journal Front Pharmacol

Date 2025 Jan 23

PMID 39845796

Authors

Hong-Yu Jiang

Bo Shao

Hong-Da Wang

Wen-Qi Zhao

Shao-Hua Ren

Yi-Ni Xu

Tong Liu

Cheng-Lu Sun

Yi-Yi Xiao

Yi-Cheng Li

Qiang Chen

Peng-Yu Zhao

Guang-Mei Yang

Xu Liu

Yu-Fan Ren

Hao Wang

Affiliations

Soon will be listed here.

Abstract

Background: The application of nanomedicine in inflammatory bowel disease (IBD) has gained significant attention in the recent years. As the field rapidly evolves, analyzing research trends and identifying research hotpots are essential for guiding future advancements, and a comprehensive bibliometric can provide valuable insights.

Methods: The current research focused on publications from 2001 to 2024, and was sourced from the Web of Science Core Collection (WoSCC). CiteSpace and VOSviewer were employed to visualize authors, institutions, countries, co-cited references, and keywords, thereby mapping the intellectual structure and identifying emerging trends in the field.

Results: The analysis covered 1,518 literature across 447 journals, authored by 9,334 researchers from 5,459 institutions and 287 countries/regions. The global publication numbers exhibited an upward trend, particularly in the last decade, with China leading as the top publishing country and the Chinese Academy of Sciences emerging as the foremost institution. Dr. Xiao Bo is the prominent figure in advanced drug delivery systems. This interdisciplinary field, which spans materials science, pharmacy, and medicine, has seen influential publications mainly concentrated on targeted nanoparticles treatment for IBD. Keyword analysis revealed that current research hotspots include drug delivery, immune cell regulation, antioxidant damage, intestinal microbiota homeostasis, and nanovesicles.

Conclusion: This study offers a comprehensive overview of global research landscape, emphasizing the rapid growth and increasing complexity of this field. It identifies key research hotspots and trends, including efforts to enhance the precision, efficacy, and safety of nanomedicine applications. Emerging directions are highlighted as crucial for further progress in this evolving area.

References

Kaplan G . The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015; 12(12):720-7. DOI: 10.1038/nrgastro.2015.150. View

Vafaei S, Esmaeili M, Amini M, Atyabi F, Ostad S, Dinarvand R . Self assembled hyaluronic acid nanoparticles as a potential carrier for targeting the inflamed intestinal mucosa. Carbohydr Polym. 2016; 144:371-81. DOI: 10.1016/j.carbpol.2016.01.026. View

van der Pol A, van Gilst W, Voors A, van der Meer P . Treating oxidative stress in heart failure: past, present and future. Eur J Heart Fail. 2018; 21(4):425-435. PMC: 6607515. DOI: 10.1002/ejhf.1320. View

Li M, Liu N, Zhu J, Wu Y, Niu L, Liu Y . Engineered probiotics with sustained release of interleukin-2 for the treatment of inflammatory bowel disease after oral delivery. Biomaterials. 2024; 309:122584. DOI: 10.1016/j.biomaterials.2024.122584. View

Adabi M, Naghibzadeh M, Adabi M, Zarrinfard M, Esnaashari S, Seifalian A . Biocompatibility and nanostructured materials: applications in nanomedicine. Artif Cells Nanomed Biotechnol. 2016; 45(4):833-842. DOI: 10.1080/21691401.2016.1178134. View

Porter R, Arends M, Churchhouse A, Din S . Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational Risks from Mechanisms to Medicines. J Crohns Colitis. 2021; 15(12):2131-2141. PMC: 8684457. DOI: 10.1093/ecco-jcc/jjab102. View

Qiu L, Shen R, Wei L, Xu S, Xia W, Hou Y . Designing a microbial fermentation-functionalized alginate microsphere for targeted release of 5-ASA using nano dietary fiber carrier for inflammatory bowel disease treatment. J Nanobiotechnology. 2023; 21(1):344. PMC: 10517557. DOI: 10.1186/s12951-023-02097-6. View

Xiao B, Laroui H, Viennois E, Ayyadurai S, Charania M, Zhang Y . Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology. 2014; 146(5):1289-300.e1-19. PMC: 3992175. DOI: 10.1053/j.gastro.2014.01.056. View

Deng Z, Rong Y, Teng Y, Mu J, Zhuang X, Tseng M . Broccoli-Derived Nanoparticle Inhibits Mouse Colitis by Activating Dendritic Cell AMP-Activated Protein Kinase. Mol Ther. 2017; 25(7):1641-1654. PMC: 5498816. DOI: 10.1016/j.ymthe.2017.01.025. View

10.

Zhu Z, Liao L, Gao M, Liu Q . Garlic-derived exosome-like nanovesicles alleviate dextran sulphate sodium-induced mouse colitis the TLR4/MyD88/NF-κB pathway and gut microbiota modulation. Food Funct. 2023; 14(16):7520-7534. DOI: 10.1039/d3fo01094e. View

11.

Zhang X, Yuan Z, Wu J, He Y, Lu G, Zhang D . An Orally-Administered Nanotherapeutics with Carbon Monoxide Supplying for Inflammatory Bowel Disease Therapy by Scavenging Oxidative Stress and Restoring Gut Immune Homeostasis. ACS Nano. 2023; 17(21):21116-21133. DOI: 10.1021/acsnano.3c04819. View

12.

Shah B, Palakurthi S, Khare T, Khare S, Palakurthi S . Natural proteins and polysaccharides in the development of micro/nano delivery systems for the treatment of inflammatory bowel disease. Int J Biol Macromol. 2020; 165(Pt A):722-737. DOI: 10.1016/j.ijbiomac.2020.09.214. View

13.

Fu Y, Wang L, Liu W, Yang L, Li L, Wang L . OX40L blockade cellular nanovesicles for autoimmune diseases therapy. J Control Release. 2021; 337:557-570. DOI: 10.1016/j.jconrel.2021.08.008. View

14.

Lamprecht A, Schafer U, Lehr C . Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res. 2001; 18(6):788-93. DOI: 10.1023/a:1011032328064. View

15.

Xiao B, Zhang Z, Viennois E, Kang Y, Zhang M, Han M . Combination Therapy for Ulcerative Colitis: Orally Targeted Nanoparticles Prevent Mucosal Damage and Relieve Inflammation. Theranostics. 2016; 6(12):2250-2266. PMC: 5135446. DOI: 10.7150/thno.15710. View

16.

Wright E, Ding N, Niewiadomski O . Management of inflammatory bowel disease. Med J Aust. 2018; 209(7):318-323. DOI: 10.5694/mja17.01001. View

17.

Fu W, Xu L, Chen Z, Kan L, Ma Y, Qian H . Recent advances on emerging nanomaterials for diagnosis and treatment of inflammatory bowel disease. J Control Release. 2023; 363:149-179. DOI: 10.1016/j.jconrel.2023.09.033. View

18.

Lee Y, Sugihara K, Gillilland 3rd M, Jon S, Kamada N, Moon J . Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. Nat Mater. 2019; 19(1):118-126. PMC: 6923573. DOI: 10.1038/s41563-019-0462-9. View

19.

Assadsangabi A, Evans C, Corfe B, Lobo A . Exploring Predictive Biomarkers of Relapse in Ulcerative Colitis: A Proteomics Approach. Inflamm Bowel Dis. 2023; 30(5):808-819. DOI: 10.1093/ibd/izad241. View

20.

Patra J, Das G, Fraceto L, Campos E, Del Pilar Rodriguez-Torres M, Acosta-Torres L . Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018; 16(1):71. PMC: 6145203. DOI: 10.1186/s12951-018-0392-8. View